Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.

Autor:	Franchi F; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Rollini F; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Kairouz V; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Rivas Rios J; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Rivas A; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Agarwal M; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Briceno M; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Wali M; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Nawaz A; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Silva G; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Shaikh Z; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Maaliki N; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Been L; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Piraino J; Division of Foot and Ankle, Department of Orthopaedic Surgery and Rehabilitation, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Pineda AM; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Suryadevara S; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Soffer D; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Zenni MM; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Jennings LK; CirQuest Labs, Memphis, Tennessee., Bass TA; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida., Angiolillo DJ; Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida.
Jazyk:	angličtina
Zdroj:	JACC. Basic to translational science [JACC Basic Transl Sci] 2019 Sep 01; Vol. 4 (7), pp. 763-775. Date of Electronic Publication: 2019 Sep 01 (Print Publication: 2019).
DOI:	10.1016/j.jacbts.2019.07.011
Abstrakt:	Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy, the PD effects of stopping aspirin in patients treated with vorapaxar also are unknown. In this prospective PD investigation, vorapaxar was associated with reduced platelet-mediated thrombogenicity without affecting clot kinetics irrespective of DM status. However, platelet-mediated thrombogenicity increased after aspirin withdrawal, particularly among patients with DM. (Optimizing anti-Platelet Therapy In diabetes MellitUS-5 Study [OPTIMUS-5]; NCT02548650). (© 2019 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu